BONCEBEK Trademark

Trademark Overview

On Monday, April 20, 2020, a trademark application was filed for BONCEBEK with the United States Patent and Trademark Office. The USPTO has given the BONCEBEK trademark a serial number of 88879919. The federal status of this trademark filing is FIFTH EXTENSION - GRANTED as of Friday, April 5, 2024. This trademark is owned by Celgene Corporation. The BONCEBEK trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals preparations, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, and cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T C...
boncebek

General Information

Serial Number88879919
Word MarkBONCEBEK
Filing DateMonday, April 20, 2020
Status734 - FIFTH EXTENSION - GRANTED
Status DateFriday, April 5, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 14, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals preparations, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, and cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical use and clinical medical use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, April 29, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901
Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events

Event DateEvent Description
Friday, April 12, 2024ITU LETTER MAILED, NO RESPONSE REQUIRED
Friday, April 12, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Saturday, April 6, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 5, 2024SOU TEAS EXTENSION RECEIVED
Friday, April 5, 2024SOU EXTENSION 5 GRANTED
Friday, April 5, 2024SOU EXTENSION 5 FILED
Friday, April 5, 2024SOU TEAS EXTENSION RECEIVED
Saturday, October 14, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 12, 2023SOU EXTENSION 4 GRANTED
Thursday, October 12, 2023SOU EXTENSION 4 FILED
Thursday, October 12, 2023SOU TEAS EXTENSION RECEIVED
Friday, April 28, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 26, 2023SOU EXTENSION 3 GRANTED
Wednesday, April 26, 2023SOU EXTENSION 3 FILED
Wednesday, April 26, 2023SOU TEAS EXTENSION RECEIVED
Friday, November 4, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 2, 2022SOU EXTENSION 2 GRANTED
Wednesday, November 2, 2022SOU EXTENSION 2 FILED
Wednesday, November 2, 2022SOU TEAS EXTENSION RECEIVED
Friday, April 29, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 27, 2022SOU EXTENSION 1 GRANTED
Wednesday, April 27, 2022SOU EXTENSION 1 FILED
Wednesday, April 27, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, November 9, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, September 14, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 14, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 14, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 14, 2021PUBLISHED FOR OPPOSITION
Thursday, August 26, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, August 26, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, August 26, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 10, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, July 23, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, July 23, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, July 23, 2021TEAS REQUEST FOR RECONSIDERATION RECEIVED
Tuesday, January 26, 2021NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, January 26, 2021FINAL REFUSAL E-MAILED
Tuesday, January 26, 2021FINAL REFUSAL WRITTEN
Tuesday, January 12, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, January 11, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, January 11, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, July 14, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, July 14, 2020NON-FINAL ACTION E-MAILED
Tuesday, July 14, 2020NON-FINAL ACTION WRITTEN
Saturday, July 11, 2020ASSIGNED TO EXAMINER
Wednesday, April 29, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, April 23, 2020NEW APPLICATION ENTERED

Related Keywords

boncebek diseases pharmaceutical preparations human disorders cancer immune anti namely system